Pictet Asset Management Holding SA Sells 48,273 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Pictet Asset Management Holding SA lowered its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 4.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,090,173 shares of the biopharmaceutical company’s stock after selling 48,273 shares during the quarter. Pictet Asset Management Holding SA owned about 1.64% of Celldex Therapeutics worth $27,549,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its position in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares during the last quarter. Swiss National Bank grew its position in Celldex Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock worth $2,964,000 after buying an additional 1,400 shares in the last quarter. KBC Group NV increased its stake in Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 1,647 shares during the period. Teachers Retirement System of The State of Kentucky raised its holdings in Celldex Therapeutics by 5.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock valued at $1,449,000 after acquiring an additional 2,070 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in shares of Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 2,705 shares during the period.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $18.15 on Tuesday. The stock’s 50 day simple moving average is $21.78 and its 200 day simple moving average is $26.06. Celldex Therapeutics, Inc. has a one year low of $17.63 and a one year high of $47.00. The firm has a market cap of $1.20 billion, a PE ratio of -7.06 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. As a group, equities analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. UBS Group initiated coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price for the company. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They issued an “overweight” rating and a $46.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th. The Goldman Sachs Group dropped their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $54.33.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.